Double Bond Pharma signed a distribution agreement with Euroresearch Srl
Double Bond Pharmaceutical (DBP) has signed an agreement with Euroresearch Srl for the distribution of their selected products on the Scandinavian market. The sales of these products will be handled by DBP’s subsidiary Drugsson AB.
The products, Biospray and Biopad, are medical devices and are used for the treatment of minor burns, skin irritation, wounds, bed sores, diaper- and incontinence rash, skin damage and abrasions, hemostat.
Drugsson will market the products to both consumers (self-care) and healthcare, which means that the products have a broad potential market.
As always, DBP makes sure that the products are of the highest quality and comply with EU directives, regulations and guidelines regarding MDR. The new legislation has already begun to apply and DBP will ensure that these are followed to the letter.
"We are pleased to sign an agreement for the distribution of new products of high need," - says Igor Lokot, CEO of DBP. – Drugsson expands with every week that passes and will continue to expand its portfolio.”
More about Euroresearch: http://www.euroresearch.biz
More about Drugsson AB: www.drugsson.com
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13 of March 2019.
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.